TOKYO (Reuters) – Japan’s Shionogi
The Phase I/II/III clinical trial of the recombinant protein vaccine known as S-268019 will be conducted in 48 children in Japan, the company said in a statement.
The vaccine has not yet been approved by the Japanese regulatory government for use in adults.
(Rocky Swift Reporting; Edited by Christopher Cushing)